Attendance fell short of 2015 conference in Las Vegas.
Manufacturers will have to apply for a new CE mark under proposed rules.
The device gained FDA approval in July 2016, becoming the second MIGS implant available in the US market.
The product is approved to treat people with wet AMD and ME after RVO, similar to the Lucentis 0.5 mg vial.
Agreement could be worth more than $300 million in licensing, milestone payments.
The product candidate did not demonstrate improvement over Eylea monotherapy at 12 weeks.
One speaker discussed how Abbott’s Symfony IOL is driving patient demand.
In one small study, SMILE and topo-guided LASIK produced similar results.
Encore Vision’s topical drops are completing Phase I/II study in 75 patients.
The iVyence excimer laser is slightly smaller than the VISX STAR S4 laser.
Products included Alcon’s NGENUITY heads-up display, Bausch + Lomb’s disposable AUTOINSERTER, and Katalyst’s 3-D printed retinal forceps grip.
Heidelberg joins Carl Zeiss Meditec and Optovue in this segment.
Allergan awaits FDA approval of neurostimulator; TearScience presents results for LipiFlow treatment.
Much of the focus was on traditional glaucoma surgery treatments.
Allergan was selected as innovator of the year in a break with the group’s tradition of honoring an individual.
The segment is expected to total $10.3 billion by 2021.
Authors say factors impeding vision health include segregation of eye care from the rest of medicine.
The France-based company said it has been contacting its suppliers to address the issue, and then it will resubmit its NDA.
The startup has partnered with Bayer to develop gene-editing cures for blindness and other diseases.
A panel that considered patient selection criteria concluded that subjects should be ages 7 to 12 with a refractive error of about -1.0D to -4.0D.
Patients saw a 43 percent reduction in mean IOP—dropping from 25.5 mmHg to 14.6 mmHg—three years after implantation.
The patient was able to perceive individual spots of light with no significant adverse side effects.
You are not currently logged in.
©2018 Market Scope
Lost your Password